Valeant Pharmaceuticals Intl Inc (VRX) Stock Scores 2 Vital Victories
By almost all accounts, Valeant Pharmaceuticals Intl Inc (NYSE:VRX) should be falling today. In simplest terms, although the drugmaker did poorly in Q2 in the aggregate, Valeant demonstrated some success in two key areas that mean the most to the market right now: debt reduction and sales of gastrointestinal drug Xifaxan. Aside from an accounting scandal — complete with the creation of a sham specialty pharmacy — the exit of a CEO and a mountain of debt, sheer distaste for its model of acquiring specialty drugs and cranking their prices up to extortion-like levels finally caught up with the company.
Source:: https://finance.yahoo.com/news/valeant-pharmaceuticals-intl-inc-vrx-142310162.html
